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The study aimed to assess the strengths and weaknesses, opportunities and threats influencing the 
achievement of prevention of mother-to-child transmission of hepatitis B virus. It also sought to 
suggest recommendations to improve the current prevention of mother-to-child transmission of 
hepatitis B virus health system in Nigeria. A critical appraisal of the prevention of mother-to-child 
transmission of hepatitis B virus health system in Nigeria was conducted. The WHO health system 
framework was used to assess the prevention of mother-to-child transmission of hepatitis B virus 
system. Considering the recent call by the World Health Organization to eliminate hepatitis and the 
existence of a robust prevention of mother-to-child transmission of human immunodeficiency virus 
health system, the prevention of mother-to-child transmission of hepatitis B virus health system in 
Nigeria is riddled with numerous challenges. These range from a health worker crisis, poor leadership 
and governance, inadequate health information, medicines, vaccines and technologies and poor 
service delivery. Urgent action in the Nigerian prevention of mother-to-child transmission of hepatitis B 
virus health system is required if Nigeria is to achieve its goal of eliminating hepatitis by 2021. 
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INTRODUCTION 
 
Hepatitis B Virus (HBV) constitutes a huge public health 
burden worldwide (WHO, 2012). It is the commonest 
cause of Chronic Liver Disease (CLD) in Nigeria (Musa et 
al., 2015). This places an enormous burden on the 
healthcare system and leads to loss of productivity in the 
active population (Su et al., 2010). HBV is vaccine-
preventable yet Nigeria is hyper-endemic (14%) for HBV 
with about 24 million infected people, majority of who are 
children and young adults (Musa et al., 2015; Forbi et al., 
2010).
 
This estimate places Nigeria as one of the most 
HBV affected countries in Africa (Ott et al., 2012). A 
recent meta-analysis showed that the pooled prevalence
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of HBV in pregnant women attending Antenatal Care 
(ANC) in Nigeria was 12% (Musa et al., 2015). This data 
represents only a fraction of all pregnant women as many 
women (about 40% or more) still do not attend ANC 
(NPC and ICF, 2014); hence it could be greater than this. 
Other studies have shown a similarly high prevalence of 
HBV in pregnant women: 8 and 11% (Olokoba et al., 
2011; Mbaawuaga et al., 2008). Mother-to-child-
transmission of HBV (MTCT-HBV) is a main route of HBV 
transmission in Nigeria
 
(Musa et al., 2015) and 
contributes significantly to the burden of HBV in the 
country. Some studies have reported HBV prevalence in 
infants as high as 12 and 17 % (Donbraye et al., 2014; 
Sadoh and Sadoh 2013). Studies in Nigeria have 
reported high HbeAg-positivity rates between 30-63% 
(Yakasai et al., 2012; Mbaawuga et al., 2008). Other 
studies in Nigeria confirmed vertical transmission rates 
between 40 and 53% (Ogunlaja et al., 2014; Onakewhor 
et al., 2001). This shows that the risk of vertical-
transmission/MTCT is high and cannot be ignored in 
Nigeria. 
The recognition of HBV as a pandemic led to the 
drafting of the Global Health Sector Strategy (GHSS) on 
Viral Hepatitis (2016-2021)
 
(WHO, 2015) by the World 
Health Organisation (WHO) and the recently released 
Global Hepatitis Report (GHR), 2017 (WHO, 2017). 
Hence, both the GHSS and GHR recommend PMTCT-
HBV as the key to breaking the cycle of ongoing HBV 
infection globally (Andersson, 2015). Without an 
accelerated response, the number of people living with 
HBV globally is estimated to remain at high levels for the 
next 40-50 years, with about 20 million deaths occurring 
between 2015 and 2030 (WHO, 2015). Nigeria will 
experience a fair share of this burden considering its 
huge population and limited resources. It is therefore 
crucial that Nigeria adopts PMTCT-HBV as a pathway to 
reducing the HBV burden in Nigeria. In response to 
reducing the burden of HBV in Nigeria, the Honorable 
Minister of Health, reiterated the Federal Government’s 
commitment to eliminating viral hepatitis by 2021 in line 
with the World Hepatitis Day, 2017 wit the theme 
“Eliminate Hepatitis”. A functional PMTCT-HBV health 
system is fundamental to reducing the HBV burden in the 
country. A health system, by the WHO is a system 
“whose primary purpose is to promote, restore, or 
maintain health”.
 
The WHO framework is composed of six 
building blocks: leadership and governance, human 
health resources, health financing, service delivery, 
medical products, vaccines and technology and health 
information systems (WHO, 2007a). 
For the above reasons, an in-depth understanding of 
the PMTCT-HBV health system in Nigeria is essential to 
provide information for policy and system development. 
The aim of this study was to conduct a critical appraisal 
of the PMTCT-HBV health system in Nigeria with a view 
to assessing its strengths and weaknesses, opportunities 
and threats influencing the achievement of  PMTCT-HBV.  
 
 
 
 
It also sought to suggest recommendations to improve 
the current PMTCT-HBV health system in Nigeria. 
 
 
METHODOLOGY 
 
This involved literature search via an internet-based search of 
websites, databases and search-engines. These include: The 
World Health Organisation (WHO) website, the Nigerian Federal 
Ministry of Health (FMoH), PubMed database and Google Scholar. 
Keywords and their synonyms used in the search strategy for the 
dissertation include: Mother-to-child-transmission (MTCT), vertical 
transmission, HBV, Nigeria, developing countries, Sub-Saharan 
Africa, health system, health services, policies. These keywords 
were chosen because they form the basis of the study topic. 
Boolean operators “AND” and “OR” were then used to obtain a final 
set of results containing all aspects of the study topic. Initial article 
selection was based on article title/abstracts. Snowballing was then 
used to identify relevant articles by scanning the references of 
those identified from the database-search.  Full-text articles were 
read for eligibility. Inclusion criteria applied to articles for this study 
referred to the objectives of the study and the quality of the 
published material. Only full text articles written in English were 
used (author reads only English); articles relevant to mother-to-child 
transmission of HBV; maternal and child health; articles on HBV in 
low-and-middle-income settings. The WHO Health system 
framework (WHO, 2007a) (Figure 1) was adopted to assess the 
PMTCT-HBV health system in Nigeria. The framework is made up 
of 6 building blocks. 
 
 
RESULTS 
 
This section is structured following the components of the 
WHO health systems framework. 
 
 
Service delivery 
 
In Nigeria, health services are delivered through tertiary, 
secondary and primary health facilities run by the 
Federal, State, and Local government tiers of 
government respectively (Okonofua et al., 2011; FMoH, 
2016a). The tertiary level of health care is provided by 
teaching hospitals and specialist hospitals. PMTCT-HBV 
services are mainly domiciled at this level, situated far 
away from majority of people, especially those in rural 
and hard-to-reach areas (Okonofua et al., 2011; FMoH 
2016a).  
The State Ministries of Health (SMoH) oversee the 
secondary level of healthcare (General and State 
hospitals) while the 774 Local Government Areas (LGAs) 
oversee the Primary Health Care (PHC) level, with 
support from the SMoH and private organisations (FMoH, 
2016a). As at December 2011, there were over 34,000 
health facilities across the country: 11,395 (33%) were 
private health facilities and 23,028 (67%) government 
health facilities. In total, 30,345 (88%); 3,993 (12%); and 
85 (1%) facilities were primary, secondary, and tertiary 
health facilities, respectively (Makinde et al., 2014). This 
is a far cry from what is expected.   
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Figure 1. The WHO health system framework (WHO, 2007a). 
 
 
 
Table 1. Types of Health facilities in Nigeria by level of management and expected coverage. 
 
Health facility Levels of management Expected numbers 
Teaching facilities Federal Government 1/State: Hence in 36 States + FCT = 37 
   
General hospitals State Government 1/LGA: Hence a minimum of 774 are expected 
   
Primary health centres Local Government 1/ward: Hence with an average of 10 wards 
  Per LGA a total of 7740 are expected 
   
Primary health clinics Local Government and 1/group of villages/neighbourhoods with about 
 WDC 2000-5000 persons 
   
Health Posts VDC/CDC 1/village or neighbourhood of about 500 persons As 
many as the number of villages 
 
FCT, Federal Capital Territory; LGA, Local Government Area; WDC, Ward Development Committee; VDC, Village Development 
Committee; CDC, Community Development Committee. Source: Minimum Standards for Primary Health Care in Nigeria (NPHCDA, 2012). 
 
 
 
Table 1 shows the expected numbers of facilities at each 
level of healthcare. 
Many of the PHC facilities which several (71%) of 
Nigerians have access to do not offer PMTCT-HBV 
services. This is due to lack of essential supplies, 
equipment and qualified staff. Although 24-h service is 
available in most tertiary and secondary health facilities, 
very few PHCs, if any in the country offer 24-h services 
(NPHCDA, 2012). The administration of Hepatitis B-birth 
Dose (HB-BD) within 24 h of birth is crucial in preventing 
MTCT-HBV, yet majority (64%) of births in Nigeria occur 
at home in the absence of a skilled provider (doctor, 
nurse, midwife or trained community health worker) with 
only 36% in health facilities
 
(NPC and ICF, 2014) leading 
to a delay in the receipt of the HB-BD and Hepatitis B 
Immunoglobulin (HBIg) which is critical in PMTCT-HBV 
(Sadoh and Eregie, 2009). Similarly, many women, 
especially in the rural areas do not receive Antenatal 
Care (ANC),
 
(Sadoh and Sadoh, 2014) with an urban: 
rural ratio of 88 %: 56 % (NBS, 2011). Those who do, 
book late during the second or third trimester (Oladokun 
et al., 2010). The ANC attendance rate in 2013 was 61
312          J. Public Health Epidemiol. 
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Figure 2. Distribution of Doctors and Nurses by zone in Nigeria. 
 
 
 
and 51% for at least one visit and 4 visits respectively 
(NPC and ICF, 2014). Screening pregnant women for 
Hepatitis B-surface Antigen (HBsAg) is a prerequisite for 
vaccination to prevent vertical transmission (Franco et al., 
2012). Unfortunately, most health facilities in Nigeria do 
not routinely screen pregnant women for HBV or offer 
vaccination services at ANC (Adekanle et al., 2015). Out 
of the 80% of mothers who received ANC in a study in 
Nigeria, only 6% of mothers were screened for HBsAg 
(Sadoh and Eregie, 2014). Some might argue that only 
those with risk factors should be screened based on cost-
effectiveness but some studies showed that majority of 
HBsAg-positive pregnant women in Nigeria had no 
identifiable risk factor, making routine screening 
important (Adeyemi et al., 2014; Okusanya et al., 2013). 
 
 
Health workforce 
 
The WHO has estimated that a minimum of 23 health 
workers for every 10,000 people is required in countries 
seeking relatively high levels of health system coverage 
for the basic needs of their populations (WHO, 2016). 
Nigeria currently has 20 health workers per 10,000 (HRH, 
2013). Impressive as the absolute figure might seem, 
Nigeria suffers from inadequate number of health 
workers. More worrisome is the inequitable distribution of 
health workers (Figure 2) with a disproportionately high 
concentration in urban areas, more in Southern Nigeria 
compared to the North especially with the current state of 
insecurity/communal clashes; in tertiary health care 
facilities and in facilities which mainly provide curative 
care. Health workers are reluctant to work in rural areas 
because of difficult working conditions, lack of continuing 
educational opportunities, shortages of medical supplies 
and equipment, or a lack of social services for their own 
families (FMoH, 2014). The frequent industrial strike 
actions by health workers also affect provision of 
PMTCT-HBV services (FMoH, 2014) (Figure 2).  
In view of the health worker shortage, the Nigerian 
government increased the number of Community Health 
Workers (CHWs) by 10,000 in the first-half of 2014 and 
proposed to have 154,800 additional CHWs by the end of 
2015, all being deployed to rural areas (FMoH, 2016a). In 
a similar manner, the Nigerian Government instituted the 
Midwives Service Scheme in 2009, as a way of 
increasing the numbers of midwives in the country though 
implementation of both schemes has been faulty 
(Abimbola et al., 2012). It is of utmost importance that 
PMTCT-HBV services are available 24 h a day/7 days a 
week in health facilities if Nigeria’s high HBV prevalence 
is to be reduced. Unfortunately, very few doctors, nurses 
and midwives can be found at the primary level of health 
care which serves majority of Nigerians. Rather, most 
PHCs are staffed by CHWs and other lower skilled 
cadres who have not been trained in PMTCT-HBV, partly 
because a national policy on PMTCT-HBV has just been 
put in place (NPHCDA, 2012). 
Studies showed that the knowledge of HBV 
management among health workers in Nigeria is low as 
only 32% of health workers were aware of the timing of 
HB-BD administration (Adeyemi et al., 2014; 
Nwokediuko, 2011). There are also misconceptions held 
by health workers concerning use of vaccine vials which 
lead to many infants missing the HB-BD, despite delivery 
in the hospital (Sadoh and Sadoh, 2014). Health 
professionals in Nigeria obtain the skills and 
competencies required to effectively care for people with 
viral hepatitis through schools for health professionals, 
on-the-job training and postgraduate training (WHO, 
2013).  
There are presently 14 professional regulatory bodies 
for maintaining standards of practice for health 
professionals. Some of them are the Medical and Dental 
Council of Nigeria, Pharmacists Council of Nigeria, 
Nursing and Midwifery Council, Community Health 
Practitioners Board, Medical Laboratory Science Council 
etc.   but   they   are   limited   by   weak   structures   and 
 
 
 
 
institutional capacities to carry out their functions (FMoH, 
2016a). 
 
 
Health information and research 
 
A National Health Research Policy and Priorities was 
developed by the Federal Ministry of Health (FMoH) in 
2014 (FMoH, 2016a). There are also Research Institutes 
and training institutions supporting learning and 
dissemination of research products, yet research is still 
underfunded in most of these institutions (FMoH, 2016a). 
Research on advances in HBV is currently carried out by 
some societies such as the Society for Gastroenterology 
and Hepatology in Nigeria (SOGHIN) and the Nigerian 
Society for Paediatric Gastroenterology Hepatology and 
Nutrition (NISPGHAN) (Eke et al., 2016). A Hepatitis 
cancer registry is maintained by the National Cancer 
Control Programme, an arm of the FMoH, yet, routine 
HBV infection surveillance are not conducted in Nigeria 
(Howell et al., 2014). While hepatitis outbreaks are 
required to be reported to the government for further 
investigation, there is inadequate laboratory capacity 
nationally to support investigation of viral hepatitis 
outbreaks and other surveillance activities (WHO, 2015). 
 
 
Medical products, vaccines and technologies 
 
Nigeria approved the addition of HB-vaccine to the 
National Program on Immunisation in 1995 but only 
became widely available in 2004 (Sadoh and Eregie, 
2008).
 
In Nigeria, the HB-vaccine is given at birth as a 
monovalent vaccine, then at 6, 10 and 14 weeks as a 
pentavalent vaccine (FMoHN, 2012). The infant 
vaccination coverage in 2011 for HBV3 was alarmingly 
low at 34% and for the birth-dose, 29%
 
(NBS, 2011), 
while HB-vaccine coverage for adults was estimated at 
41% in 2013 (GAVI, 2014). The constant availability of 
potent vaccines requires a functional cold chain system. 
This is sadly not the case in Nigeria which has led to the 
absence of vaccines in some health facilities (FMoHN, 
2012). The Cold Chain Assessment (CCA) of the 
National Programme on Immunisation in Nigeria showed 
that 43% of cold chain equipment at the local government 
and health facility levels was non-functional (FMoHN, 
2012). 
 
 
Financing 
 
The Nigerian Government with support from the Global 
Alliance for Vaccines and Immunisation (GAVI, 2014) 
routinely provides HB-vaccines at no cost to infants while 
couples provide HBIg for their exposed babies 
(Onakewhor et al., 2013). The cost of 1 vial of HBIg is 
about ₦360,000 ($100) (Ezeonu et al., 2014) which is 
unaffordable     for     majority    of    parents.   This    was 
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consistent with a study in Nigeria (Ogunlaja et al., 2014) 
who showed that only 25% of women who were HBsAg-
positive could afford HbIg due to the high cost. Majority of 
the population live below the minimum wage of ₦18,000 
($50) with an average monthly income of ₦1000 ($5) 
(Abdulraheem et al., 2012). The cost of screening is 
₦1000 ($2.7) in some tertiary facilities which is still 
prohibitive for the population’s majority (Onakewhor et al., 
2013). 
Evidence shows that payment for PMTCT services 
mainly out-of-pocket or within the National Health 
Insurance Scheme (NHIS), which has limited coverage 
(Adeyemi et al., 2013). Less than 5% of the population is 
currently covered by any form of health insurance. Only 
Federal Government workers are currently enrolled in 
social health insurance and civil servants from most 
states are yet to be enrolled (FMoH, 2016a). Currently, 
only women in formal employment are covered by the 
health scheme which leaves out majority of poor 
unemployed women who cannot afford such services 
(Okonofua et al., 2011). WHO suggests that governments 
should aim at allocating a minimum of 5% of Gross 
Domestic Product (GDP) for health spending (Savedoff, 
2003). Meanwhile, in Nigeria, 4.15% allocated to the 
health sector in the 2017 budget proposal falls short of 
the minimum 15% recommended by the Abuja 
Declaration of 2001 decided by African heads of state at 
a meeting. There is also no specific line item for tracking 
financial resources for PMTCT-HBV at all levels (FMoH, 
2016b). 
 
 
Leadership and governance 
 
In 2013, the Nigerian Government through the FMoH 
established the Viral Hepatitis Control programme within 
the National AIDS and STI Control Programme (NASCP). 
But it was only in July 2015, that the Nigerian 
Government developed a national policy on viral hepatitis 
B control and a draft copy of the strategic plan for the 
control of viral hepatitis B (FMoH, 2015a; FMoH, 2015b). 
 
During the World Hepatitis Day, 2017, with the theme 
“Eliminate Hepatitis”, the Minister of Health reiterated the 
commitment of the Federal Government to eliminate viral 
hepatitis by 2021 in line with the global commitment. 
Other policies which operate in Nigeria include the 
National Policy on screening of blood and blood products 
and the National Policy on injection safety in health-care 
settings (FMoH, 2006). It is also not known whether it is 
mandatory for healthcare workers to be vaccinated 
against HBV prior to starting work that might put them at 
risk of exposure to blood and blood products. This will 
also prevent the transfer of nosocomial infections from 
workers to their patients (WHO, 2015). Despite the 
existence of national policies, majority of healthcare 
providers do not have a management protocol for HBV in 
pregnancy (Ezeonu et al., 2014). The absence of hospital
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Table 2. Strengths, Weakness, Opportunities and Threats of the PMTCT-HBV health system in Nigeria. 
 
Strengths Weaknesses 
Availability of PMTCT-HIV services in both the public and 
private sectors in many states  
Hepatitis control programmes are largely donor dependent 
and donor support is likely to decrease 
Approximately 20 health workers/10000 persons  Low access to care because most people have low 
awareness of the need for prevention, early detection and 
treatment and cannot afford the cost of care 
Available capacity for training more human resources  Majority cannot afford the cost of care. The cost of Hepatitis 
B immunoglobulin is high. 
 
The National Health Act aims to improve health care 
financing through the Basic Health Care Provision Fund 
Inequitable distribution of the health care workforce 
 
The Viral Hepatitis Strategic Plan is designed to leverage 
on the National Health Insurance Scheme (NHIS) Act- this 
could bring health insurance coverage to more Nigerians 
and promote disease prevention, data collection and 
reporting, and quality improvement. 
Inequitable distribution of available PMTCT health care 
facilities. Majority are in tertiary institutions. 
The National Viral Hepatitis Policy and National Strategic 
Plan (2016-2020) focuses on improving universal access 
to quality and affordable care and rapidly scale up services 
 
Nigeria has developed a strong health care infrastructure 
to provide chronic care for people living with HIV. This can 
be extended to viral hepatitis 
 
HBV surveillance can be added easily to the already 
existing routine surveillance for other infections  
 
Presence of regulatory bodies  
Opportunities Threats 
The commitment of the Federal Government to eliminate 
viral hepatitis by 2021 in line with the global commitment. 
National hepatitis health awareness programmes 
celebrated on World Hepatitis Day sponsored by the FMoH 
and relevant stakeholders 
 
PMTCT is still give low priority in the health care system 
The interest in PMTCT has increased at the global and 
national level  
Facilities for PMTCT are yet to be put in place in PHCs 
Primary health care facilities are available in every local 
government area with potential for developing public 
PMTCT health services 
Inadequate human and financial capacity to provide and 
manage PMTCT health services 
Task shifting leading to training of CHWs translating to an 
increase in the availability of skilled health care during 
home deliveries 
Poor knowledge of and attitudes towards PMTCT  
 
 Migration of health care workers to other countries for 
“greener pastures” 
 
 Meagre budgetary allocations to health care at all levels of 
governance 
 
 
 
policies on PMTCT-HBV may hinder effective control of 
HBV (Adekanle et al., 2015).  
Per the WHO health system framework
 
(WHO, 2007a), 
the PMTCT-HBV health system in Nigeria still has some 
shortfalls. PMTCT-HBV services are not readily available 
nor accessible to majority of the Nigerian populace. Most 
of the services available especially at the tertiary centres 
focus on curative rather than preventive care (WHO, 
2000). The health workforce is also inadequate to meet 
the health care needs of the populace. In summary, the 
Nigerian PMTCT-HBV health system is not sufﬁcient to 
respond to the needs of the populace. These problems 
highlight the need for an analysis of the strengths, 
weaknesses,     opportunities     and     threats    (Table 2) 
 
 
 
 
associated with the PMTCT-HBV health system to proffer 
solutions.  
 
 
DISCUSSION 
 
The PMTCT-HBV health system in Nigeria is weak and 
riddled with challenges, thus underperforming across all 
building blocks as highlighted in the results above. 
Nigeria’s health system performance by the WHO in 2000 
was abysmally low with a rank of 187 out of 191 countries 
(WHO, 2000). In 2017, the situation is not any different. It 
is worrisome that the exact numbers of health facilities 
offering PMTCT-HBV services in Nigeria is unknown
 
(FMoH, 2016a) and that majority of these services are 
concentrated in the few tertiary centers, and to a lesser 
extent the secondary facilities (FMoH, 2016a). To tackle 
this problem, a need assessment of health facilities and 
implementation of findings needs to be carried out by the 
FMoH to identify the gaps. PHCs need to be equipped 
with resources for routine screening to improve access to 
the majority in rural-settings. Considering that only 36% 
of deliveries occur in health facilities,
 
(NPC and ICF, 
2014) scaling up skilled attendance at birth during home 
deliveries is of utmost importance. This is feasible due to 
the ongoing policy of task-shifting using CHWs but will 
require extensive engagement of both public and private 
sectors (FMoH, 2014). Studies have shown the 
effectiveness of home-visits by CHWs in improving other 
interventions like malaria treatment and breastfeeding 
practices (Findley et al., 2013). The role of Traditional 
Birth Attendants (TBAs) should not be overlooked, due to 
their high demand especially in the Northern part of 
Nigeria where 22% of deliveries had a TBA in 
attendance. TBAs can aid in hard-to-reach areas 
especially in the wake of the lingering Boko Haram crisis 
in the North-East (NPC and ICF, 2014). The TBAs can be 
trained and supervised by higher cadre of health 
professionals. TBAs have been used successfully in 
Malawi and Cameroon to implement PMTCT services in 
areas where women had limited access to skilled-staff 
delivery (Hamela et al., 2014; Findley et al., 2013). 
The relatively heat-stable nature of the Hepatitis-B 
vaccine and its use in a safe single-dose (Uniject®) 
makes it suitable for use in home visits Outside the Cold 
Chain (OCC) (Sutanto et al., 1999). The National Primary 
Health Care Development Agency (NPHCDA, 2012) and 
National Programme on Immunisation (NPI) should 
explore ways of improving the cold chain and OCC to 
reach home-births. In Indonesia, the use of Hepatitis-B 
vaccine OCC by village midwives to all new-borns led to 
an increase in vaccine coverage and minimal vaccine 
wastage (Wang et al., 2015). In a Randomised Controlled 
Trial conducted in rural China, the two study arms with 
home-visits by village health workers witnessed a 
significantly greater increase in birth-dose coverage, from 
11  to  68%  and  from  7  to  77%, respectively,  than  the 
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group which relied on vaccination in town-clinics, with a 
lower coverage increase from 8 % to 58 % (Hamela et 
al., 2014). 
The health work force is the crux of any health system 
hence the shortage and inequitable distribution of health 
workers needs to be solved. Task-shifting needs to be 
scaled up as several studies have shown that lower 
cadres of health personnel are capable of effectively 
delivering PMTCT-HBV services when compared to 
higher cadres. Training, retraining, provision of 
appropriate technology and supportive supervision are 
what is required to make this effective (FMoH, 2014). The 
FMoH and heads of facilities should also develop 
guidelines on integrating HBV into existing healthcare 
programmes especially HIV. This is organisationally 
feasible because both HIV and HBV have shared 
approaches hence it is easy to make use of the HIV 
prevention-infrastructure to address the problem of 
MTCT-HBV (Andersson, 2015). This also leads to better 
utilisation of scarce human and financial resources 
(Lemoine et al., 2015). The scale up of PMTCT-HBV 
services requires reliable and timely information to 
provide evidence-based information. Emphasis should be 
placed on a nationwide electronic medical record system 
(EMRS) and this needs to involve the PHCs and all 
PMTCT-HBV providers (WHO, 2007b).  
Viral load testing should also be incorporated into 
existing ANC services for HBV infected mothers (FMoH, 
2015a). Point-of-care (POC) tests for HBsAg and HBeAg 
detection are currently available, affordable and need 
minimal training and can be used in low-resource settings 
(Arora et al., 2013). Their performance has been 
validated in both Europe and Sub-Saharan Africa. In the 
Gambia, and Tanzania, sensitivity and specificity of two 
HBsAg POC tests have been observed to be precise 
(Njai et al., 2014; Khuroo et al., 2014).  
HBV research should be encouraged and funding 
made available to carry out such research.  Research 
and operational projects on HBV are very scarce in Sub-
Saharan Africa hence increasing knowledge on global 
HBV prevalence and risk factors for transmission should 
be a priority through well-defined epidemiological 
surveys. The PROLIFICA programme in The Gambia and 
Senegal is one of the few addressing the issue of HBV 
testing, severity assessment of chronic hepatitis B and 
screening of liver cancer. It also aims at demonstrating 
the efficacy of Tenofovir-based antiviral therapy for 
preventing cirrhosis and hepatocellular carcinoma in 
West Africa (Lemoine et al., 2015).  
The high cost of the HBIg and antiviral medications is 
another major challenge. The Federal Government needs 
to improve access to the vaccine and medication by 
reducing cost. This can be done in collaboration with 
organizations like GAVI and other donors. Alternative 
solutions to overcome the barriers of cost do exist. 
Nigeria can learn from Trade-Related Aspects of 
Intellectual  Property  Rights  experiences  of  Egypt  and 
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India in obtaining antiviral drugs at low prices (Lemoine et 
al., 2015). Social protection schemes like the NHIS 
should also be scaled up to cater for the majority who are 
not in the employ of the Federal Government. Viral 
hepatitis testing can be included as a preventive service 
in the NHIS scheme (FMoH, 2015a). Community-based 
health insurance system for the poor has proven to be 
effective in countries like Mexico, Brazil, Bangladesh and 
Cambodia, Guinea, Mauritania (Ahmed et al., 2016; 
Macinko et al., 2015). 
 
 
Conclusion 
 
This paper has tried to assess the PMTCT-HBV health 
system by making use of the WHO building blocks of 
leadership and governance, service delivery, health 
manpower, financing, medicines, vaccines and 
technologies and health information. Suggestions have 
also been made towards improving this health system 
before Hepatitis B Virus becomes a pandemic too difficult 
for the world to handle. The fight against HBV requires a 
multi-sectoral approach and strong political will on the 
part of the government for Nigeria to attain its goal of 
eliminating hepatitis by 2021. 
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